Given that CAD requires comprehensive clinical management, performing standard thyroid hormone testing prior to coronary angiography and calculating the FT3/FT4 ratio to evaluate early perturbations in thyroid hormone homeostasis may facilitate the early identification of mid-/high-risk patients and the development of individualized prevention and treatment strategies. The gene discussed is TG; the disease is coronary artery disorder.